Sharon Manne1, Deborah Kashy2, Terrance Albrecht3, Yu-Ning Wong4, Anne Lederman Flamm5, Al B Benson6, Suzanne M Miller4, Linda Fleisher4, Joanne Buzaglo7, Nancy Roach8, Michael Katz9, Eric Ross4, Michael Collins10, David Poole4, Stephanie Raivitch4, Dawn M Miller11, Tyler G Kinzy12, Tasnuva Liu12, Neal J Meropol11. 1. Cancer Institute of New Jersey, New Brunswick, NJ, USA (SM). 2. Department of Psychology, Michigan State University, East Lansing, MI, USA (DK) 3. Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA(TA) 4. Fox Chase Cancer Center, Philadelphia, PA, USA (Y-NW, SMM, LF, ER, DP, SR) 5. Department of Bioethics, Center for Ethics, Humanities & Spiritual Care, Cleveland Clinic, Cleveland, OH, USA (ALF) 6. Robert H.Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA (ABB) 7. Cancer Support Community, Washington, DC, USA (JB) 8. Colorectal Cancer Coalition, Alexandria, VA, USA (NR) 9. International Myeloma Foundation, North Hollywood, CA, USA (MK) 10. Medical College of Wisconsin, Milwaukee, WI, USA (MC) 11. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA (DMM, NJM) 12. University Hospitals Seidman Cancer Center, Cleveland, OH, USA (TGK, TL)
Abstract
OBJECTIVE: This study used the Ottawa Decision Support Framework to evaluate a model examining associations between clinical trial knowledge, attitudinal barriers to participating in clinical trials, clinical trial self-efficacy, and clinical trial preparedness among 1256 cancer patients seen for their first outpatient consultation at a cancer center. As an exploratory aim, moderator effects for gender, race/ethnicity, education, and metastatic status on associations in the model were evaluated. METHODS: . Patients completed measures of cancer clinical trial knowledge, attitudinal barriers, self-efficacy, and preparedness. Structural equation modeling (SEM) was conducted to evaluate whether self-efficacy mediated the association between knowledge and barriers with preparedness. RESULTS: . The SEM explained 26% of the variance in cancer clinical trial preparedness. Self-efficacy mediated the associations between attitudinal barriers and preparedness, but self-efficacy did not mediate the knowledge-preparedness relationship. CONCLUSIONS: . Findings partially support the Ottawa Decision Support Framework and suggest that assessing patients' level of self-efficacy may be just as important as evaluating their knowledge and attitudes about cancer clinical trials.
OBJECTIVE: This study used the Ottawa Decision Support Framework to evaluate a model examining associations between clinical trial knowledge, attitudinal barriers to participating in clinical trials, clinical trial self-efficacy, and clinical trial preparedness among 1256 cancerpatients seen for their first outpatient consultation at a cancer center. As an exploratory aim, moderator effects for gender, race/ethnicity, education, and metastatic status on associations in the model were evaluated. METHODS: . Patients completed measures of cancer clinical trial knowledge, attitudinal barriers, self-efficacy, and preparedness. Structural equation modeling (SEM) was conducted to evaluate whether self-efficacy mediated the association between knowledge and barriers with preparedness. RESULTS: . The SEM explained 26% of the variance in cancer clinical trial preparedness. Self-efficacy mediated the associations between attitudinal barriers and preparedness, but self-efficacy did not mediate the knowledge-preparedness relationship. CONCLUSIONS: . Findings partially support the Ottawa Decision Support Framework and suggest that assessing patients' level of self-efficacy may be just as important as evaluating their knowledge and attitudes about cancer clinical trials.
Entities:
Keywords:
Ottawa Decision Support Framework; cancer clinical trials; cancer patients
Authors: Ann Cranney; Annette M O'Connor; Mary J Jacobsen; Peter Tugwell; Jonathan D Adachi; Daylily S Ooi; Lisa Waldegger; Rose Goldstein; George A Wells Journal: Patient Educ Couns Date: 2002-07
Authors: L Baider; E Andritsch; B Uziely; G Goldzweig; P Ever-Hadani; G Hofman; G Krenn; H Samonigg Journal: Crit Rev Oncol Hematol Date: 2003-04 Impact factor: 6.312
Authors: P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: James R Wright; Timothy J Whelan; Susan Schiff; Sacha Dubois; Dauna Crooks; Patricia T Haines; Diane DeRosa; Robin S Roberts; Amiram Gafni; Kathleen Pritchard; Mark N Levine Journal: J Clin Oncol Date: 2004-11-01 Impact factor: 44.544
Authors: Michael S Simon; Wei Du; Lawrence Flaherty; Philip A Philip; Patricia Lorusso; Cheryl Miree; Daryn Smith; Diane R Brown Journal: J Clin Oncol Date: 2004-04-13 Impact factor: 44.544
Authors: M Lizette Rangel; Natalia I Heredia; Belinda Reininger; Lorna McNeill; Maria E Fernandez Journal: J Cancer Educ Date: 2019-12 Impact factor: 2.037
Authors: Deevakar Rogith; Rafeek A Yusuf; Shelley R Hovick; Bryan M Fellman; Susan K Peterson; Allison M Burton-Chase; Yisheng Li; Elmer V Bernstam; Funda Meric-Bernstam Journal: Int J Med Inform Date: 2016-01-18 Impact factor: 4.046
Authors: Alan L Kaplan; Catherine M Crespi; Josemanuel D Saucedo; Sarah E Connor; Mark S Litwin; Christopher S Saigal Journal: Cancer Date: 2014-05-09 Impact factor: 6.860
Authors: Ryan D Nipp; Hang Lee; Elizabeth Powell; Nicole E Birrer; Emily Poles; Daniel Finkelstein; Karen Winkfield; Sanja Percac-Lima; Bruce Chabner; Beverly Moy Journal: Oncologist Date: 2016-03-14
Authors: Yu-Ning Wong; Mark D Schluchter; Terrance L Albrecht; Al Bowen Benson; Joanne Buzaglo; Michael Collins; Anne Lederman Flamm; Linda Fleisher; Michael Katz; Tyler G Kinzy; Tasnuva M Liu; Sharon Manne; Seunghee Margevicius; Dawn M Miller; Suzanne M Miller; David Poole; Stephanie Raivitch; Nancy Roach; Eric Ross; Neal J Meropol Journal: J Clin Oncol Date: 2015-12-23 Impact factor: 44.544
Authors: Neal J Meropol; Yu-Ning Wong; Terrance Albrecht; Sharon Manne; Suzanne M Miller; Anne Lederman Flamm; Al Bowen Benson; Joanne Buzaglo; Michael Collins; Brian Egleston; Linda Fleisher; Michael Katz; Tyler G Kinzy; Tasnuva M Liu; Seunghee Margevicius; Dawn M Miller; David Poole; Nancy Roach; Eric Ross; Mark D Schluchter Journal: J Clin Oncol Date: 2015-12-23 Impact factor: 44.544